Current and new antitumor necrosis factor agents in perspective.
Maini
Ravinder N
RN
Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK. r.maini@imperial.ac.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D014409:Tumor Necrosis Factor-alpha